（NaOH-P）,hydrochloric acid bound phosphorus（HCl-P）,residual phosphorus（Re-P）.The dissolved orthophosphate accounts for only 24.35%of the total phosphorus in the biogas slurry,and the particulate phosphorus（PP+NaOH-P+HCl-P）accounts for 53.72%of the total phosphorus.The experiment found that the biogas residue biochar is mainly used to absorb the dissolved orthophosphate in the biogas slurry,indicating that the particulate phosphorus has a large potential for conversion and utilization in the adsorption and recovery of phosphorus system.Therefore,it is difficult to adsorb and recover by using small molecular organic acids.The particulate phosphorus is converted into orthophosphate which can be adsorbed and utilized by the biogas residue-based biomass charcoal.（6）The organic acid intensification conversion test showed that the three organic acids,tartaric acid,citric acid and acetic acid,can promote the particulate phosphorus（PP）or agglomerate phosphorus（NaOH-P+HCl-P）in the biogas slurry to the soluble orthophosphoric acid.The salt（Ortho-P）is released and its conversion ability is:citric acid>tartaric acid>acetic acid.At a concentration of 5mmol/L,citric acid mainly interacts with the protonic acid effect anion complexing effect,which increases the Ortho-P in the biogas slurry by 174.08%;tartaric acid is mainly a ligand ion,which increases the Ortho-P in the biogas slurry.78.97%;acetic acid mainly promotes the increase of Ortho-P in biogas slurry by 27.79%in molecular form.And tartaric acid and citric acid use chelation and dissolution to promote the release of poorly soluble calcium（magnesium）salt in biogas slurry or phosphorus adsorbed by calcium magnesium oxide and hydrated oxide,and release of phosphorus adsorbed by iron and aluminum.The main mechanism is competitive adsorption.（7）After the biogas slurry of biogas residue-based biochar was adsorbed,the radish pot experiment was carried out by using the recovered product,and it was found that the soil pH,cation exchange amount,soil alkaline nitrogen,available phosphorus and available potassium all increased with the application level of the recovered product.And there is an increasing trend.The total phosphorus and available phosphorus in the seedling stage of the bio-liquid phosphorus recovery product were lower than that of the chemical fertilizer control,but the rosette stage and the fleshy root expansion period were significantly higher than the chemical fertilizer control,indicating that the phosphorus recovery product of the biogas slurry phosphorus was associated with the growth and development of the radish.A slow release effect has occurred.The recovery product treatment increased the vitamin C and total sugar content of the radish,and also reduced the content of the harmful nitrate,and the treatment of the phosphorus replacement fertilizer was 70%.Therefore,the bioreactor-based biochar adsorbs the biogas slurry and the recovered product can not only improve the soil fertility status,but also release the phosphorus during the growth period of the radish,and at the same time improve the quality of the radish.After waking up Wednesday morning and brewing a potent dose of coffee, I scrounged in the closet for the day’s attire.
I picked out my Demolition Derby tee-shirt, a souvenir from a long-ago trip to visit family in Ohio that I only wear when I’m in a peculiar frame of mind. It fit the mood on my first day of self-imposed quarantine against catching the coronavirus bug.
Like just about everyone else at lakeside, I was finally realizing the proximity of the pandemic was for real. The fact that I’m in the vulnerable age group was sinking in, making me ponder how to stay safe and best spend the idle weeks or months that lay ahead.
A first thought was to launch into a thorough spring cleaning of the homestead. It promises dual accomplishments of de-cluttering the premises and eradicating any cooties lurking around to threaten my family’s health. There’s plenty of purging to do, surely enough to stay occupied until Easter rolls around.<reponame>christydennison/ResumeStripClub
var PDFViewerSrvc = require('./PDFViewerSrvc')();

module.exports = function () {
    var MainSrvc = {};

    MainSrvc.loadPDF = function(pdfName) {
        PDFJS.getDocument(pdfName).then(function(pdfDocument) {
            PDFViewerSrvc.pdfViewer.setDocument(pdfDocument);

            // pdfDocument.getPage(1).then(function(page) {
            //     var scale = 1.5;
            //     var viewport = page.getViewport(scale);

            //     var context = PDFViewerSrvc.element.getContext('2d');
            //     PDFViewerSrvc.element.height = viewport.height;
            //     PDFViewerSrvc.element.width = viewport.width;

            //     var renderContext = {
            //       canvasContext: context,
            //       viewport: viewport
            //     };
            //     page.render(renderContext);

            //     setTimeout(function() {
            //         PDFViewerSrvc.findText('hello');
            //     }, 100);
            // });
            setTimeout(function() {
                PDFViewerSrvc.findText('hello');
            }, 100);
        });
    }

    return MainSrvc;
};Our own vaccine
Human trials to start this month, results in October. This is reason enough to prioritise Govt funding to R&D
When the going gets tough, the tough get going. And this is exactly what India’s innovators, scientists and researchers have shown in the face of the Coronavirus pandemic, most of them as self-starters. A potential COVID-19 vaccine, the first to be developed in India, has been given the Drug Controller General of India’s (DCGI) approval for Phase I and II human clinical trials that are scheduled to start across the country this month. Results are expected to be out by October, following which larger clinical trials will be conducted. The vaccine has been developed by Hyderabad-based Bharat Biotech, which has delivered more than four billion doses of vaccines worldwide and also created vaccines for H1N1 and rotavirus in the past. COVAXIN, developed by Bharat Biotech in collaboration with the National Institute of Virology and the Indian Council for Medical Research (ICMR), is an inactivated vaccine, created from a strain of the infectious SARS-CoV-2 virus that has shown promise in pre-clinical studies, demonstrating extensive safety and effective immune responses. The good news is that apart from COVAXIN, four or five other home-grown vaccines are in early stages of development, too. Zydus Cadilla is working on two vaccines while Biological E, Indian Immunologicals and Mynvax are developing one each. The rapid strides that are being made is proof that not for nothing is the country among the largest manufacturers of generic drugs and vaccines in the world. It is home to half a dozen major vaccine makers and a host of smaller ones, making doses against stubborn diseases like polio, meningitis, pneumonia rotavirus, BCG, measles, mumps and rubella.
When we began our fight against the pandemic, there was an atmosphere of fear and gloom in the country over the fact that our healthcare facilities were inadequate. We did not have enough PPEs, testing kits or ventilators and the general consensus was that with the West and China having massive resources at their disposal to pump into research, they would be the first ones to come out with the drugs and vaccines to treat Coronavirus. A vast majority of Indians were resigned to the fact that even if the vaccine did come out, it would reach us after a considerable time lapse as the rich and developed nations would get it first because of their money power and clout. If anything, the pandemic has unleashed our determination to find our own solutions since the world is starved of resources. It has also made it imperative for us to invest in research and development, so far neglected and supported by corporates. After testing kits, ventilators and even making our own PPE kits — we are now exporting the last — we have been innovating at a rapid pace. We have also developed robots powered by Artificial Intelligence to clean Covid wards and look after patients in isolation wards. The biggest news in the fight against the virus came on June 21 when the DCGI granted permission to Glenmark Pharmaceuticals to manufacture and sell Favipiravir and also gave Cipla and Hetero emergency marketing approval for Remdesivir for treating severe COVID-19 patients. We may have not been the first off the block where the vaccine is concerned as the ones developed by Moderna Inc, China’s Sinovac Biotech and UK’s Oxford-AstraZeneca are set to enter late-stage trials, but the fact remains that we will be independent and not look to the West or the dragon to tackle our emergency. Our researchers and scientists have shown that not for nothing are they considered the best minds in the business.
Source: The PioneerI am thinking about buying the Remington model 700 SPS DM. I am not sure if I want to go with a stainless finish or if the finish on the SPS DM is just as good. If there is